{"classes":[{"categories":[{"measurements":[{"comment":"Insufficient number of participants with events.","groupId":"OG000","lowerLimit":"10.6","upperLimit":"NA","value":"13.3"},{"groupId":"OG001","lowerLimit":"4.8","upperLimit":"16.6","value":"8.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"20"}],"units":"Participants"}],"description":"Measure of clinical benefit, defined as the duration from study enrollment to death.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with a deleterious mutation in one of the following genes: BRCA1, BRCA2, PALB2, RAD51C, or RAD51D.","id":"OG000","title":"Rucaparib Cohort A"},{"description":"Participants with a deleterious mutation in one of the following genes: BARD1, BRIP1, FANCA, NBN, RAD51, or RAD51B.","id":"OG001","title":"Rucaparib Cohort B"}],"paramType":"MEDIAN","populationDescription":"Safety Population - all enrolled participants who received at least 1 dose of protocol-specified treatment.","reportingStatus":"POSTED","timeFrame":"From first dose of study drug until disease progression (up to approximately 2 years)","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"month"}